BioWorld

June 2, 2006

Cangene Gets $362M Contract Under BioShield For Botulism

The U.S. government has contracted with the Canadian firm Cangene Corp. on a $362 million agreement for a botulism treatment, the first award for that potential bioterror agent. (BioWorld Today) Read More

Proteolix Series B: $45M To Boost Proteasome Program

New Research Helps Explain Neurology Drug Mechanisms

Ambion Spin-Off Asuragen Brings In $49M Via Series A

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...